The mechanism by which quaternized anticholinergic bronchodilators permeate the airway epithelium remains controversial to date. In order to elucidate the role of drug transporters, ipratropium bidirectional transport as well as accumulation and release studies were performed in layers of the broncho-epithelial cell line Calu-3 grown at an air-liquid interface, in presence or absence of a range of transporter inhibitors. Unexpectedly, a higher transepithelial permeability was observed in the secretory direction, with an apparent efflux ratio > 4. Concentration-dependent and inhibitor studies demonstrated the drug intracellular uptake was carrier-mediated.
INTRODUCTION
Anticholinergic bronchodilators are the first line therapeutic agents in the pharmacological 2 management of Chronic Obstructive Pulmonary Disease (COPD) 1 . In order to maximise local drug 3 concentrations in the lung with reduced systemic exposure, these drugs are administered by 4 inhalation. Although their quaternary ammonium structure renders these molecules too polar to 5 cross biological barriers, their engagement with the drug target on airway smooth muscles and 6 their rapid absorption 2,3,4 (Tmax~5 minutes) following inhalation demonstrate their ability to cross 7 the lung epithelial barrier. However, the absorption mechanism, i.e., drug transporter-mediated vs 8 passive diffusion is not entirely clear. 9 The lungs express a range of transporters belonging to both the ATP-binding cassette (ABC) and 10 solute carrier (SLC) families 5, 6 . It has been hypothesised that polyspecific organic cation 11 transporters (OCT/Ns) belonging to the SLC22 superfamily of drug carriers, may play a role in the 12 lung disposition of the anticholinergic bronchodilators 7 . The short-acting ipratropium and the long- 13 acting tiotropium are indeed recognised substrates for OCT1, OCT2 and OCTN2 while OCT3 only 14 transports ipratropium and the OCTN1 subtype has a low affinity for both compounds 8,9,10 . 15 Interactions between the more recently approved long-acting glycopyrronium and OCTs have not 16 been systematically explored to date. Nevertheless, OCT1 and OCT2 are known to transport the 17 drug 8 . 18 In agreement with uptake experiments in OCT/N transfected cells, it has been shown that both 19 ipratropium and tiotropium are internalised by the human bronchial epithelial cell line BEAS-2B 20 via an OCTN2-mediated mechanism 11 . In addition, the transporter was also reported to be involved 21 in the accumulation of the short-acting bronchodilator in the tracheal epithelium of mice in vivo 9 . 22 More recently, a study in various lung epithelial cell lines highlighted the role of the OCT/N 23 5 carriers in the intracellular accumulation of ipratropium, with different subtypes playing a 1 prominent role depending on the cell line 12 . 2 However, in contradiction with drug uptake data, the absorption of ipratropium in isolated perfused 3 rat lungs (IPRL) following intra-tracheal delivery was unaffected by a pre-administration of a high 4 concentration of the drug or of the OCT1-3 inhibitor MPP + , suggesting it is primarily mediated by 5 passive diffusion 12 . Drug uptake studies in undifferentiated lung cells and absorption measurement 6 in intact lungs therefore led to contradictory conclusions regarding the role of drug transporters in 7 the trans-epithelial permeability of anticholinergic bronchodilators. 8 Due to their low intrinsic permeability across cell membranes, charged molecules may exploit 9 uptake and efflux transporters to enter or exit the cells, respectively 13 . To unravel the role of 10 transporters in the permeability of drug molecules across biological barriers, epithelial monolayer 11 systems are considered invaluable. For instance, the potential impact of carrier-mediated transport 12 on the oral bioavailability of various cationic molecules was demonstrated in intestinal Caco-2 13 monolayers 14, 15 . However, to date, no such systematic investigation has been undertaken with 14 inhaled cationic anticholinergic bronchodilators in a permeability model that anatomically 15 represents the lung epithelium. 16 Amongst available human airway in vitro models, the bronchial epithelial cell line Calu-3 is the 17 most extensively used for investigating drug transport characteristics 16, 17 . When cultured at an air- 18 liquid interface (ALI) on permeable supports, Calu-3 cells form tight layers that resemble the 19 native bronchial epithelium 18, 19 and are able to predict drug absorption in rat lungs 20 . Importantly, 20 Calu-3 layers express the range of drug transporters found in normal human bronchial epithelial 21 cell layers grown in similar conditions if maintained for 21 days at the ALI 21 . More specifically, 22 we have shown that the same OCT subtypes were present in both models, i.e., OCT1, OCT3, 23 6 OCTN1 and OCTN2 with an OCT activity detected on the apical side of the Calu-3 layers 22, 23 . experimentation and only data obtained in layers which had maintained a TEER above this 22 threshold at the end of the study were considered for analysis. was assessed following the same protocol. The barrier properties of the Calu-3 layers were verified by measuring the permeability of the 3 paracellular marker, fluorescein isothiocyanate-dextran (FITC-dextran, average molecular weight 4 3,000-5,000 Da) at a concentration of 0.5 mg/mL following the experimental protocol described Permeability data were obtained from at least three layers and the apparent permeability coefficient 12 (Papp) was calculated using the equation below. 
Drug uptake studies

19
The role of drug transporters on ipratropium cell uptake was investigated after drug exposure from 20 both the apical and basolateral sides of the ALI Calu-3 cell layers. The incubation and experimental 21 conditions were similar to those described above except that the drug solution was withdrawn from 
Drug release studies
11
For initial drug release studies, cell layers were pre-loaded with ipratropium (10 µM) from their 12 apical side. After 45 minutes of incubation, the drug solution was aspirated from the donor 13 compartment and the cell layers were given a quick wash with cold PBS, three times. They were 14 then exposed to 500 µL HBSS from both the apical and basolateral sides. The release of the 15 accumulated drug was studied by collecting 50 µL from both compartments over 2 h. Each sample 16 was replaced with 50 µL blank HBSS. 17 Ipratropium release was then monitored in the presence of various inhibitors. The experimental 18 design was similar to that mentioned above, except that cell layers were pre-loaded with 19 ipratropium (10 µM) for only 5 minutes. After a quick wash with cold PBS, the cell layers were 20 incubated with 500 µL HBSS with or without inhibitors on both their apical and basolateral sides. (1100 Series, Agilent Technologies) HPLC system . Working stocks were prepared in methanol 10 and a 12 point calibration curve (CC) was prepared in HBSS ranging from 0.24 to 500 nM utilized 11 for each analyte. Sample quantitation was achieved by fitting curves to a weighted linear regression 12 (1/concentration 2 ). Quality control (QC) samples prepared in blank HBSS were interspersed 13 between study samples to monitor batch performance. Batch acceptance was set at within ±20 % 14 of the nominal concentration for each standard and QC sample. 15 Chromatographic separation was achieved by an ACE Excel 2 C18-AR (50 x 2.1mm) column with 16 a mobile phase consisting of methanol: water with 0.1% v/v formic acid. A gradient 17 chromatographic method was used, where the % of methanol was increased from 45 to 90 within 18 2 minutes and maintained for 1 minute, before returning to the initial level of 45% within another 19 3.5 minutes. The flow rate was set at 0.3 mL/min. Sample temperature was kept at 4 o C, and 20 column temperature was set at 40 o C. 21 The retention time was determined as 1. The results are presented as mean ± standard deviation (n = 3-4 layers). GraphPad Prism version 8 6 was used for statistical analysis. The normal distribution of initial transport and uptake data 9 consisting of n ≥ 5 was confirmed and thereafter, assumed for all data sets. Unpaired t-test was 10 used to compare two groups and ANOVA with Dunnett's multiple comparison test was used for 11 more than 2 groups. A p value < 0.05 was considered as indicative of statistical significance. 
15
As a common mechanism of transepithelial transport was suspected for the three bronchodilators, 16 the study was pursued with only ipratropium. Concentration dependent permeability 17 measurements showed a trend towards a decrease in a-b transport with an increase in the apical 18 donor concentration, the Papp value being significantly lower at 100 and 300 µM than at 10 µM 19 ( Figure 3 ). In contrast, increasing ipratropium basolateral concentration up to 300 µM had no effect 20 on its secretory Papp (Figure 3 ).
21
Ipratropium transport across Calu-3 ALI layers was subsequently studied in presence of a range of Verapamil is commonly used as a P-glycoprotein (P-gp) inhibitor 26 but has also been shown to 5 interfere with the activity of a range of drug transporters, including some of the Multidrug 6 Resistance Proteins (MRPs) 27 , multidrug and toxin extrusion (MATE) transporters 28 and all the 7 OCTs 7 . Probenecid is known to inhibit the MRPs without affecting P-gp 27 and although it also 8 interacts with the Organic Anion Transporters (OATs) 29 , we have shown previously that these 9 proteins are not expressed in Calu-3 ALI layers 21 .
10
MPP + significantly reduced ipratropium Papp in both the absorptive and secretory directions. Interestingly, the extent of the reduction in permeability was similar in both directions; i.e.,~30% 
Uptake studies
22
In order to gain a better understanding of the role of transporters in ipratropium trafficking across 1 ALI Calu-3 layers, drug uptake measurements were undertaken in presence or absence of 2 transporter inhibitors. As verapamil is known to interact with multiple transporter families, it was 3 not tested as an inhibitor in those studies. 4 Ipratropium cell-associated concentration was first quantified after a 5 min apical or basolateral 5 exposure. That was significantly higher when the drug had been added in the apical chamber 6 ( Figure 5 ), likely as a consequence of carrier-mediated internalisation at the air interface. 7 Both the apical and basolateral uptake of ipratropium by Calu-3 layers was significantly inhibited 8 to~50% of the control in presence of MPP + ( Figure 6 ). On the other hand, TEA caused a dramatic 9 reduction (~14 % of control) in ipratropium uptake from the apical side without affecting the 10 uptake from the opposite side ( Figure 6 ). Probenecid impact on ipratropium internalisation was 11 intriguingly similar to that of TEA. Indeed, it largely inhibited the apical uptake (~10% of control) 12 but had no effect on the internalisation from the opposite side ( Figure 6 ). This is in contradiction 13 with its alleged interactions with an MRP transporter and indicates it interferes with the activity of 14 an uptake transporter in Calu-3 layers. 16 The ability of ipratropium to be secreted across either membrane of Calu-3 cell layers was assessed 17 following a 45 minute pre-loading from the apical side. Indeed, the drug concentrations in the 18 basolateral compartment were below the quantification limit of the LC-MS/MS method after a 5 19 minute pre-exposure. 20 Ipratropium showed a preferential efflux into the apical compartment, the drug apical 21 concentrations being~13 -60 times higher than in the basolateral chamber throughout the course 22 of the study (Figure 7) , which confirmed the presence of a secretory mechanism across the apical 1 membrane of Calu-3 layers, as suggested by the bi-directional transport studies. 2 The mechanism behind the efficient secretion of ipratropium at the air-epithelium interface was 3 further explored by monitoring its release into the apical compartment following a 5 minute apical 4 pre-incubation in the presence of inhibitors. Interestingly, both MPP + and TEA significantly 5 reduced the release of intracellular ipratropium into the apical compartment to~20 % of the control 6 while probenecid caused a~50% decrease ( Figure 7 ). This showed that all three inhibitors 7 impacted on transporters involved in both the uptake and release of ipratropium at the luminal side 8 of the Calu-3 cell layers. 10 Since it has been suggested organic cations might interact with negatively charged sites within the 11 tight junctions, potentially affecting paracellular diffusion 30 , the permeability of FITC-dextran 12 across Calu-3 layers was measured with or without ipratropium, TEA or MPP + in the test medium. 13 FITC-dextran was selected as the paracellular marker due to its relatively high molecular weight.
Drug release studies
Effect of organic cations on FITC-dextran permeability
14 Any alteration of the tight junctions is likely to have a more significant impact on its trans- 15 epithelial permeability than on that of a small molecule like mannitol or fluorescein. 16 The dye Papp was unchanged in the presence of ipratropium or TEA but was significantly reduced 17 by MPP + (Figure 8 ). This indicates the latest compound might partly obstruct the paracellular space it has been proposed OCT/Ns facilitate their transport across the airway epithelium 11 . On the other 4 hand, absorption studies in IPL failed to demonstrate an involvement of the transporters, 5 suggesting it is primarily driven by passive diffusion 12 . Given the importance of anticholinergic 6 bronchodilators in the management of COPD, gaining further insight into the mechanisms by 7 which they are processed by lung cells could help optimising their therapeutic benefits. 8 In this study, we used ALI human broncho-epithelial Calu-3 layers, a physiologically relevant in bronchodilators across the bronchial epithelium is likely governed by a complex process involving 16 an inter-play between paracellular passive diffusion and transporter mediated uptake/efflux across 17 the apical cell membrane. 18 The three anticholinergic bronchodilators tested, i.e., ipratropium, tiotropium and glycopyrronium, 19 exhibited a polarised transport across Calu-3 cell layers, with, unexpectedly, a higher permeability 20 in the b-a direction (Figure 2 ). This implies the presence of a secretion mechanism across the layers 21 that is more efficient than absorption processes facilitated by uptake transporters such as OCT/Ns. Increasing ipratropium donor concentrations caused a significant reduction in its permeability in 6 the a-b direction while b-a transport was unaffected over the range investigated (Figure 3 ). 7 Furthermore, the OCT inhibitors TEA and MPP + decreased the drug absorptive transport while all 8 inhibitors tested but L-carnitine limited its secretory permeability ( Figure 4 ). It is noteworthy that 9 the effect of MPP + on trans-epithelial transport must be interpreted with caution due to its impact 10 on FITC-dextran permeability (Figure 8 ). These observations nevertheless demonstrated drug 11 transporters play a significant role in ipratropium asymmetric permeability across Calu-3 layers, 12 although drug uptake and release studies were required to fully understand their contribution. 13 To account for a suspected high unspecific binding of the drug to cell membranes, ipratropium 14 uptake in the layers was primarily evaluated in presence of inhibitors. However, the higher cell- ipratropium, is a hydrophilic cation with a low membrane permeability 13 . This phenomenon has 10 been proposed to contribute to metformin relatively high oral bioavailability by creating a 11 sustained concentration gradient across the intestinal absorption barrier that enhances its diffusion 12 by the paracellular route. A similar modulation of ipratropium concentration gradients across both 13 Calu-3 cell membranes by apical transporters might account for the reduction of its absorptive 14 transport in the cell layers at high concentrations as well as by TEA and MPP + (Figures 3 & 4) , 15 whereas, overall, our data suggests it is primarily governed by paracellular passive diffusion. In Importantly, Calu-3 layers provided a unique insight into the mechanism of drug transport from 22 the blood circulation into the lung tissue, which is extremely challenging to investigate in a whole Calu-3 layers or even, in the bronchial epithelium. Similarly, the MPP + sensitive basolateral uptake 16 transporter remains to be unravelled. This is unlikely to be an OCT member since its activity is 17 unaffected by TEA ( Figure 6 ). 18 The clinical relevance of our findings in differentiated Calu-3 layers remains to be determined. 19 However, if the carrier-mediated 'luminal recycling' of ipratropium observed in vitro also occurs 20 in vivo in epithelial cells, it may participate in the control of the local drug concentrations in the 21 lung tissue by creating a 'drug depot' in the airway epithelium. This could influence exposure of 22 the smooth muscles to ipratropium and therefore, the drug therapeutic efficacy. Furthermore, the anatomically relevant cell culture models of the airway epithelium is essential to gain 12 understanding on the mechanisms controlling drug disposition in the lungs. 13 
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